CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma
James L. Rubenstein,Valerie S. Wong,Cigall Kadoch,Hua Xin Gao,Ramon F. Barajas,Lingjing Chen,S. Andrew Josephson,Brian J. Scott,Vanja C. Douglas,Mekhala Maiti,Lawrence D. Kaplan,Patrick A. Treseler,Soonmee Cha,Jimmy Hwang,Paola Cinque,Jason G. Cyster,Clifford A. Lowell +16 more
Reads0
Chats0
TLDR
It is demonstrated for the first time that elevated CXCL13 concentration in cerebrospinal fluid (CSF) is prognostic and that CXC chemokine ligand and IL-10 mediate chemotaxis of lymphoma cells isolated from CNS lymphoma lesions.About:
This article is published in Blood.The article was published on 2013-06-06 and is currently open access. It has received 178 citations till now. The article focuses on the topics: Lymphoma & CXCL13.read more
Citations
More filters
Journal ArticleDOI
Lyme neuroborreliosis—epidemiology, diagnosis and management
TL;DR: There is evidence that patients with post-treatment Lyme disease syndrome do not have ongoing B. burgdorferi infection and, thus, do not benefit from additional antibiotic therapy, and most patients who receive this diagnosis have other illnesses.
Journal ArticleDOI
CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond
TL;DR: The complex networks of cellular interactions involving tumoral CXCL13 and CXCR5 integrate to promote cancer cell autonomous and non-autonomous responses, highlighting the relevance of autocrine and paracrine interactions in dictating the cancer phenotype.
Journal ArticleDOI
How I treat CNS lymphomas
TL;DR: The goal is to provide an overview of current knowledge regarding the pathogenesis of CNS lymphomas and to highlight promising strategies that the authors believe to be most effective in establishing diagnosis, staging, and therapeutic management.
Journal ArticleDOI
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
James L. Rubenstein,Huimin Geng,Eleanor J. Fraser,Paul Formaker,Lingjing Chen,Jigyasa Sharma,Phoebe Killea,Kaylee Choi,Jenny Ventura,John Kurhanewicz,Clifford A. Lowell,Jimmy Hwang,Patrick A. Treseler,Penny K. Sneed,Jing Li,Xiaomin Wang,Nianhang Chen,Jon A. Gangoiti,Pamela N. Munster,Bertil Damato +19 more
TL;DR: It is concluded that lenalidomide penetrates ventricular CSF and is active as monotherapy in relapsed CNS lymphomas and delays whole brain radiotherapy (WBRT) in patients with inadequate responses to lenalidumide.
References
More filters
Journal ArticleDOI
CXCL13 Is Required for B1 Cell Homing, Natural Antibody Production, and Body Cavity Immunity
TL;DR: In mice lacking the chemokine, CXCL13, B1 cells are deficient in peritoneal and pleural cavities but not in spleen, providing insight into the mechanism of B1 cell homing and establishing a critical role for B1cell compartmentalization in the production of natural antibodies and for body cavity immunity.
Journal ArticleDOI
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas.
Bastian Malzkorn,Marietta Wolter,Franziska Liesenberg,Michael Grzendowski,Kai Stühler,Helmut E. Meyer,Guido Reifenberger +6 more
TL;DR: These studies revealed miRNA‐specific influences on the viability, proliferation, apoptosis and invasive growth properties of A172 and T98G glioma cells in vitro and suggest miR‐17 and miR-184 as interesting candidates contributing to gliomas progression.
Journal ArticleDOI
The safety and efficacy of stereotactic biopsy for intracranial lesions.
TL;DR: Stereotactic brain biopsy is considered by many physicians to have significant morbidity and mortality rates with a high risk of sampling error resulting in misdiagnosis.
Journal Article
Inhibition of Interleukin 10 by Rituximab Results in Down-Regulation of Bcl-2 and Sensitization of B-cell Non-Hodgkin’s Lymphoma to Apoptosis
TL;DR: It is demonstrated that one mechanism by which Rituximab sensitizes NHL to chemotherapeutic drugs is mediated through down-regulation of antiapoptotic IL-10 autocrine/paracrine loops and Bcl-2.
Related Papers (5)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Andrés J.M. Ferreri,Michele Reni,Marco Foppoli,Maurizio Martelli,Gerasimus A. Pangalis,Maurizio Frezzato,Maria Giuseppina Cabras,Alberto Fabbri,Gaetano Corazzelli,Fiorella Ilariucci,Giuseppe Rossi,Riccardo Soffietti,Caterina Stelitano,Daniele Vallisa,Francesco Zaja,Lucia Zoppegno,Gian Marco Aondio,Giuseppe Avvisati,Monica Balzarotti,Alba A. Brandes,José Luis Crespo Fajardo,Henry L. Gomez,Attilio Guarini,Graziella Pinotti,Luigi Rigacci,Catrina Uhlmann,Piero Picozzi,Paolo Vezzulli,Maurilio Ponzoni,Emanuele Zucca,Federico Caligaris-Cappio,Franco Cavalli +31 more
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more